Profile data is unavailable for this security.
About the company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
- Revenue in USD (TTM)65.00k
- Net income in USD-279.42m
- Incorporated2017
- Employees232.00
- LocationAllogene Therapeutics Inc210 East Grand AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 457-2700
- Fax+1 (302) 636-5454
- Websitehttps://allogene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Third Harmonic Bio Inc | 0.00 | -32.74m | 514.54m | 42.00 | -- | 1.99 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
4D Molecular Therapeutics Inc | 20.22m | -109.89m | 518.14m | 201.00 | -- | 0.8797 | -- | 25.63 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Alumis Inc | 0.00 | -189.03m | 529.89m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Q32 Bio Inc | 0.00 | -65.02m | 539.68m | 41.00 | -- | 16.02 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Celcuity Inc | 0.00 | -82.59m | 556.93m | 55.00 | -- | 3.15 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Allogene Therapeutics Inc | 65.00k | -279.42m | 564.60m | 232.00 | -- | 1.10 | -- | 8,686.17 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Cartesian Therapeutics Inc | 54.10m | -229.65m | 585.87m | 38.00 | -- | -- | -- | 10.83 | -38.41 | -38.41 | 5.07 | -5.69 | 0.2221 | -- | 2.89 | 1,423,737.00 | -94.26 | -43.66 | -106.38 | -66.84 | -- | -- | -424.47 | -136.35 | -- | -0.3153 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Scholar Rock Holding Corp | 0.00 | -203.85m | 593.84m | 150.00 | -- | 4.44 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Exscientia PLC (ADR) | 27.57m | -169.98m | 594.57m | 483.00 | -- | 1.50 | -- | 21.57 | -1.33 | -1.33 | 0.2169 | 3.06 | 0.042 | -- | 26.88 | 57,082.93 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 610.92m | 285.00 | -- | 2.55 | -- | 167.79 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 620.72m | 110.00 | -- | 2.54 | -- | 40.95 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Savara Inc | 0.00 | -75.29m | 628.77m | 37.00 | -- | 5.19 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 631.11m | 100.00 | -- | 6.62 | -- | 7.29 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Neurogene Inc | 925.00k | -55.44m | 631.36m | 91.00 | -- | 4.07 | -- | 682.55 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 25.36m | 12.15% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.18m | 4.40% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.11m | 3.89% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 8.04m | 3.85% |
PRIMECAP Management Co.as of 30 Jun 2024 | 5.67m | 2.72% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.12m | 1.97% |
JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 3.61m | 1.73% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.11m | 1.49% |
Geode Capital Management LLCas of 30 Jun 2024 | 2.82m | 1.35% |
Woodline Partners LPas of 31 Mar 2024 | 2.63m | 1.26% |